Published in Lancet Infect Dis on September 01, 2010
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis (2014) 2.75
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28
Size and usage patterns of private TB drug markets in the high burden countries. PLoS One (2011) 2.02
Ribosome. The structure of the human mitochondrial ribosome. Science (2015) 1.82
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. Proc Natl Acad Sci U S A (2011) 1.66
Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests. J Infect Dis (2014) 1.65
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol (2014) 1.46
The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet (2012) 1.41
New developments in aminoglycoside therapy and ototoxicity. Hear Res (2011) 1.35
Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol (2011) 1.32
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One (2012) 1.23
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis (2014) 1.23
Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol (2013) 1.20
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis (2013) 1.17
Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother (2012) 1.16
Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol (2012) 1.06
Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment. PLoS One (2011) 1.06
Diagnosis and interim treatment outcomes from the first cohort of multidrug-resistant tuberculosis patients in Tanzania. PLoS One (2013) 1.06
Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One (2013) 1.02
Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol (2014) 1.02
Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol (2014) 1.00
High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India. PLoS One (2013) 0.98
Management of drug-resistant spinal tuberculosis with a combination of surgery and individualised chemotherapy: a retrospective analysis of thirty-five patients. Int Orthop (2011) 0.97
Tuberculosis chemotherapy in the 21 century: Back to the basics. Lung India (2011) 0.97
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
Treatment of drug-resistant tuberculosis. Lancet Infect Dis (2011) 0.95
A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol (2014) 0.94
Cosubstrate tolerance of the aminoglycoside resistance enzyme Eis from Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 0.94
Periprosthetic joint infections: clinical and bench research. ScientificWorldJournal (2013) 0.94
Genome Analysis of the First Extensively Drug-Resistant (XDR) Mycobacterium tuberculosis in Malaysia Provides Insights into the Genetic Basis of Its Biology and Drug Resistance. PLoS One (2015) 0.93
A common mechanism of inhibition of the Mycobacterium tuberculosis mycolic acid biosynthetic pathway by isoxyl and thiacetazone. J Biol Chem (2012) 0.92
Quantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice. PLoS One (2015) 0.91
Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa. PLoS One (2013) 0.91
Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother (2014) 0.89
Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. BMC Infect Dis (2013) 0.89
Synthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analogues. PLoS One (2013) 0.88
Prevalence of Tuberculosis, Drug Susceptibility Testing, and Genotyping of Mycobacterial Isolates from Pulmonary Tuberculosis Patients in Dessie, Ethiopia. Tuberc Res Treat (2015) 0.87
Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery. Antimicrob Agents Chemother (2012) 0.86
Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance. Front Cell Infect Microbiol (2013) 0.85
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in Mycobacterium tuberculosis. ACS Med Chem Lett (2013) 0.85
Resistance to antibiotics targeted to the bacterial cell wall. Protein Sci (2014) 0.85
A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. PLoS One (2012) 0.84
Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study. J Antimicrob Chemother (2014) 0.84
Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism. J Biol Chem (2012) 0.84
Clinical applications of drug desensitization in the Asia-Pacific region. Asia Pac Allergy (2011) 0.84
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? Br J Clin Pharmacol (2015) 0.84
Quantification and validation of ertapenem using a liquid chromatography-tandem mass spectrometry method. Antimicrob Agents Chemother (2014) 0.83
Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open (2014) 0.83
Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis. Expert Rev Anti Infect Ther (2012) 0.83
XDR tuberculosis. Lancet Infect Dis (2011) 0.82
New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Infect Dis Rep (2016) 0.81
In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Sci Rep (2015) 0.81
Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N. PLoS One (2013) 0.81
Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients. Antimicrob Agents Chemother (2016) 0.80
Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. Oncotarget (2016) 0.80
Medical Management of Drug-Resistant Tuberculosis. Tuberc Respir Dis (Seoul) (2015) 0.79
Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. Am J Trop Med Hyg (2014) 0.79
TuberQ: a Mycobacterium tuberculosis protein druggability database. Database (Oxford) (2014) 0.79
Bibliometric analysis of worldwide publications on multi-, extensively, and totally drug - resistant tuberculosis (2006-2015). Multidiscip Respir Med (2017) 0.79
Reinterpreting the mechanism of inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by D-cycloserine. Biochemistry (2013) 0.79
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microbes Infect (2016) 0.78
Accurate Detection of Rifampicin-Resistant Mycobacterium Tuberculosis Strains. Sensors (Basel) (2016) 0.77
Cytoskeletal proteins of actinobacteria. Int J Cell Biol (2012) 0.77
Induction of mycobacterial resistance to quinolone class antimicrobials. Antimicrob Agents Chemother (2012) 0.77
Drug-resistant tuberculosis in two children in Greece: report of the first extensively drug-resistant case. Eur J Pediatr (2012) 0.77
Systematic analysis of cell cycle effects of common drugs leads to the discovery of a suppressive interaction between gemfibrozil and fluoxetine. PLoS One (2012) 0.77
Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. Lung India (2012) 0.76
Tuberculosis in patients with haematological malignancies. Mediterr J Hematol Infect Dis (2014) 0.76
Reducing the price of treatment for multidrug-resistant tuberculosis through the Global Drug Facility. Bull World Health Organ (2015) 0.76
Small molecule deubiquitinase inhibitors promote macrophage anti-infective capacity. PLoS One (2014) 0.76
Physiology and substrate specificity of two closely related amino acid transporters, SerP1 and SerP2, of Lactococcus lactis. J Bacteriol (2014) 0.76
The use of functional genomics in conjunction with metabolomics for Mycobacterium tuberculosis research. Dis Markers (2014) 0.75
The Relationship between Extensively Drug-Resistant Tuberculosis and Multidrug-Resistant Gram-Negative Bacilli. PLoS One (2015) 0.75
General and advanced diagnostic tools to detect Mycobacterium tuberculosis and their drug susceptibility: a review. Eur J Clin Microbiol Infect Dis (2015) 0.75
Use of siRNA molecular beacons to detect and attenuate mycobacterial infection in macrophages. World J Exp Med (2015) 0.75
Synergistic interactions of MmpL3 inhibitors with antitubercular compounds in vitro. Antimicrob Agents Chemother (2017) 0.75
Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol Toxicol (2015) 0.75
Crystallization and preliminary crystallographic analysis of the first condensation domain of viomycin synthetase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.75
Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China. Antimicrob Agents Chemother (2016) 0.75
The Global Drug Facility as an intervention in the market for tuberculosis drugs. Bull World Health Organ (2015) 0.75
High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China. Sci Rep (2016) 0.75
Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens. Am J Ther (2015) 0.75
Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorg Med Chem (2015) 0.75
A DECADE TREND OF MULTIDRUG RESISTANT TUBERCULOSIS IN SÃO PAULO STATE, BRAZIL. Rev Inst Med Trop Sao Paulo (2016) 0.75
Treatment of drug-resistant tuberculosis. Lancet Infect Dis (2011) 0.75
Microchip-based ultrafast serodiagnostic assay for tuberculosis. Sci Rep (2016) 0.75
A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis. PLoS One (2016) 0.75
The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity. Int J Nanomedicine (2016) 0.75
Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. J Thorac Dis (2016) 0.75
Factors Associated with Fatality during the Intensive Phase of Anti-Tuberculosis Treatment. PLoS One (2016) 0.75
The Non-Essential Mycolic Acid Biosynthesis Genes hadA and hadC Contribute to the Physiology and Fitness of Mycobacterium smegmatis. PLoS One (2015) 0.75
Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States. Tuberc Res Treat (2016) 0.75
Bioinformatics Identification of Drug Resistance-Associated Gene Pairs in Mycobacterium tuberculosis. Int J Mol Sci (2016) 0.75
Thyroid function in multidrug-resistant tuberculosis patients with or without human immunodeficiency virus (HIV) infection before commencement of MDR-TB drug regimen. Afr Health Sci (2016) 0.75
Clinical outcomes for multi- and extensively drug resistant tuberculosis patients with adjunctive resectional lung surgery in Beijing, China. J Thorac Dis (2017) 0.75
Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann Clin Microbiol Antimicrob (2017) 0.75
First use of bedaquiline in a patient with XDR-TB in Singapore. BMJ Case Rep (2015) 0.75
Validation of housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques (2004) 6.42
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet (2010) 4.95
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet (2010) 4.71
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69
Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study. Lancet (2009) 4.53
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2009) 4.14
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis (2013) 3.12
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J (2012) 3.00
Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet (2002) 2.92
Immunological biomarkers of tuberculosis. Nat Rev Immunol (2011) 2.88
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ (2008) 2.66
Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. Lancet (2003) 2.64
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J (2012) 2.61
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol (2006) 2.61
Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med (2009) 2.55
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J (2012) 2.47
Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study. PLoS One (2011) 2.40
Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS (2005) 2.38
Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis (2012) 2.29
Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J (2013) 2.20
Progress towards improved tuberculosis diagnostics for developing countries. Lancet (2006) 2.16
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J (2013) 2.08
Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther (2007) 2.06
Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 2.05
Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One (2010) 2.03
Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol (2006) 1.99
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med (2010) 1.73
Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol (2005) 1.72
Lung remodeling in pulmonary tuberculosis. J Infect Dis (2005) 1.71
Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med (2015) 1.71
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One (2011) 1.70
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PLoS One (2012) 1.69
Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69
Severe acute respiratory syndrome vs. the Middle East respiratory syndrome. Curr Opin Pulm Med (2014) 1.69
Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J Clin Microbiol (2007) 1.63
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
Reversing the tide of the UK tuberculosis epidemic. Lancet (2013) 1.61
Drug-resistant tuberculosis: past, present, future. Respirology (2010) 1.58
Cost-effectiveness of treating latent tuberculous infection: a step towards elimination? Int J Tuberc Lung Dis (2013) 1.58
Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS One (2008) 1.56
BCG: the story continues. Lancet (2005) 1.55
Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trialsgroup study. Am J Respir Crit Care Med (2009) 1.54
Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J (2012) 1.54
Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr (2006) 1.49
Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol (2004) 1.48
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia. Eur Respir J (2012) 1.45
Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement. Eur Respir J (2012) 1.44
Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. Lancet (2003) 1.43
Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis (2008) 1.43
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
Tuberculosis elimination: theory and practice in Europe. Eur Respir J (2014) 1.42
Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses. J Pediatr (2002) 1.42
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis (2010) 1.41
Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control. Tuberculosis (Edinb) (2011) 1.40
New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med (2011) 1.40
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
Incidence of venous thromboembolism in tuberculosis patients. Respiration (2004) 1.38
Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon. BMC Res Notes (2008) 1.37
Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting. PLoS One (2009) 1.34
Identifying predictors of interferon-γ release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study. Am J Respir Crit Care Med (2012) 1.30
Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J Immunol Methods (2005) 1.29
Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis (2007) 1.29
Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis (2012) 1.28
Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF. Eur Respir J (2012) 1.28
Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.23
Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med (2010) 1.23
Extensively drug-resistant tuberculosis: epidemiology and management challenges. Infect Dis Clin North Am (2010) 1.23
Tuberculosis control is crucial to achieve the MDGs. Lancet (2010) 1.22
Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med (2014) 1.20
The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Soc Sci Med (2002) 1.19
How great is the risk of Middle East respiratory syndrome coronavirus to the global population? Expert Rev Anti Infect Ther (2013) 1.19
A case of a progressive multifocal leukoencephalopathy patient with four different JC virus transcriptional control region rearrangements in cerebrospinal fluid, blood, serum, and urine. J Neurovirol (2005) 1.19
Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS (2012) 1.18
Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar. Clin Vaccine Immunol (2010) 1.17
Progress and challenges in childhood tuberculosis. Lancet Infect Dis (2013) 1.16
Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology (2004) 1.15
Thoracic empyema: current opinions in medical and surgical management. Curr Opin Pulm Med (2010) 1.14
Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther (2008) 1.12
Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa. Trop Med Int Health (2010) 1.11
Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Trop Med Int Health (2010) 1.10
High rates of congenital cytomegalovirus infection linked with maternal HIV infection among neonatal admissions at a large referral center in sub-Saharan Africa. Clin Infect Dis (2013) 1.10
In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med (2005) 1.10
Tuberculosis in prisons in sub-Saharan Africa--a potential time bomb. S Afr Med J (2011) 1.10
Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control. Clin Chest Med (2009) 1.10